

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) is pleased to announce that Cobamamide Capsules (0.5mg) (the “**Product**”) developed by the Group have obtained the drug registration approval issued by the National Medical Products Administration of the People’s Republic of China and are deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

The Product is a type of vitamin B12 drugs indicated for the treatment of megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy. It may also be used as an adjunct therapy for nutritional disorders and leukopenia caused by radiation and drugs.

The approval of the Product will further enrich the Group’s product portfolio in the therapeutic areas of hematology and neurology.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 5 June 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.